www.fdanews.com/articles/122305-epiphany-phase-iib-shingles-trial-yields-positive-results

Epiphany: Phase IIb Shingles Trial Yields Positive Results

November 18, 2009

Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection.
redOrbit